GlaxoSmithKline's Votrient gets US panel nod for renal cancer
This article was originally published in Scrip
GlaxoSmithKline's oral anti-angiogenic Votrient (pazopanib) won the overwhelming endorsement of the US FDA's oncologic drugs advisory panel for treating advanced renal cell carcinoma. The agency's experts voted 10 to zero that the anticancer agent had a favourable risk/benefit profile, despite the drug's hepatic risks.
You may also be interested in...
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.
Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.
Agency’s briefing document for 15 January review of the fixed-dose product combining an opioid and nonsteroidal anti-inflammatory reflects application of opioid benefit/risk framework described in June draft guidance.